Becton Dickinson & Co (XTER:BOX)
€ 214.5 0.2 (0.09%) Market Cap: 62.03 Bil Enterprise Value: 78.65 Bil PE Ratio: 39.00 PB Ratio: 2.58 GF Score: 70/100

Becton Dickinson and Co at UBS Genomics 2.0 and MedTech Innovations Summit Transcript

Aug 11, 2021 / 11:00PM GMT
Release Date Price: €200.33 (+0.59%)
Matthew Charles Taylor
UBS Investment Bank, Research Division - Equity Research Analyst of Medical Supplies & Devices

Welcome to the next session here. I'm Matt Taylor, UBS' medical supplies and devices analyst, and I'm pleased to finally be talking about something I know something about. This is great.

We thought this would be kind of a cool transition actually for the conference. Obviously, the first half is focused mainly on genomics and life science tools and tomorrow will be a lot of med tech, and we have Becton kind of in the middle.

And to help us make that transition. We have leaders from the Life Sciences group, including Dave Hickey, who's EVP and President of Life Sciences; and Puneet Sarin, the President of Biosciences; and also Kristen Stewart, Head of Strategy and Investor Relations.

And so for this session, we're going to have a short presentation, and then we'll do a fireside chat Q&A. And as always, if you want to ask questions, you can just key in with the instructions on your tables.

So without further ado, let me introduce, well, Kristen

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot